 Equities.com | FDA Gives The 'OK' In Biggest News For This Medical Device Company To Date Seeking Alpha To be precise, C-Pulse is being developed for the treatment of Stage III Heart Failure, which accounts for 25%-30% of heart failure cases or 1.5 million patients. The news, among other things, is a major de-risking event for shareholders and investors ... Sunshine Heart Announces Conditional Approval of IDE From the FDA for C ... Sunshine Heart Gets Conditional FDA Investigational Device Exemption ... From Earlier: Sunshine Heart Announces Conditional FDA Approval for IDE for C ... |
